| | Datamonitor - Monoclonal Antibodies in Asthma: The choice between life and breath? - Market Analysis Report (Site not responding. Last check: ) |
 | | Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified. |
 | | Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator. |
 | | Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market. |
| www.datamonitor.com /~43e2d1aa906c4ab59502625d927202a1~/industries/research/?pid=BFHC0719 (310 words) |